KNSA // Kiniksa Pharmaceuticals International plc (Class A)
ANR <GO> NASDAQ RQD COCKPIT → CIK 0001730430 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$90.80 ▼ -1.44
(-1.56%)
MKT CAP: $7.25B • VOL: 999.0K
52W L $37 52W H $98
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$76
MEDIAN
$102
MEAN
$104
HIGH
$123
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KNSA TAPE
KNSA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $109.87 | $104.42 | 2025-02-14 | $82.63 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $114.41 | $107.14 | 2025-02-06 | $85.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $103.51 | $99.88 | 2025-01-29 | $87.17 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $92.62 | — | 2025-01-17 | $88.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $79.90 | $86.26 | 2025-01-09 | $80.81 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $108.05 | $94.43 | 2024-12-18 | $79.00 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $88.08 | $91.71 | 2024-12-04 | $84.44 | -4.3% | 48% | C |